NCT00194129 - Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions

Bipolar Disorder

Interventions

DRUG

Lithium

Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.

DRUG

Divalproex

Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.

DRUG

Placebo

Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.

Trial Locations (1)

University Hospitals of Cleveland, Cleveland